Impact BioMedical, Inc. (IBO) - Total Liabilities
Based on the latest financial reports, Impact BioMedical, Inc. (IBO) has total liabilities worth $27.06 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IBO cash generation efficiency to assess how effectively this company generates cash.
Impact BioMedical, Inc. - Total Liabilities Trend (2016–2024)
This chart illustrates how Impact BioMedical, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Impact BioMedical, Inc.'s assets to evaluate the company's liquid asset resilience ratio.
Impact BioMedical, Inc. Competitors by Total Liabilities
The table below lists competitors of Impact BioMedical, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Korea Refract
KO:010040
|
Korea | ₩110.26 Billion |
|
Auric Mining Ltd
AU:AWJ
|
Australia | AU$2.05 Million |
|
Demire Deutsche Mittelstand Real Estate AG
F:DMRE
|
Germany | €705.58 Million |
|
Haranga Resources Ltd
AU:HAR
|
Australia | AU$551.93K |
|
Baltic Sea Properties AS
OL:BALT
|
Norway | Nkr881.60 Million |
|
Panorama Sentrawisata Tbk
JK:PANR
|
Indonesia | Rp724.87 Billion |
|
European Metals Holdings Ltd
AU:EMH
|
Australia | AU$795.83K |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
USA | $41.97 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Impact BioMedical, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Impact BioMedical, Inc. market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Impact BioMedical, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Impact BioMedical, Inc. (2016–2024)
The table below shows the annual total liabilities of Impact BioMedical, Inc. from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $13.05 Million | -20.27% |
| 2023-12-31 | $16.37 Million | +18.39% |
| 2022-12-31 | $13.83 Million | +1219.63% |
| 2021-12-31 | $1.05 Million | +1242.96% |
| 2020-12-31 | $78.03K | +259.17% |
| 2019-12-31 | $21.72K | +8.12% |
| 2018-12-31 | $20.09K | -21.01% |
| 2017-12-31 | $25.44K | +354.23% |
| 2016-12-31 | $5.60K | -- |
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application … Read more